Mutant KRAS is a druggable target for pancreatic cancer
Khvalevsky, Elina Zorde, Gabai, Racheli, Rachmut, Itzhak Haim, Horwitz, Elad, Brunschwig, Zivia, Orbach, Ariel, Shemi, Adva, Golan, Talia, Domb, Abraham J., Yavin, Eylon, Giladi, Hilla, Rivkin, Ludmila, Simerzin, Alina, Eliakim, Rami, Khalaileh, Abed, Hubert, Ayala, Lahav, Maor, Kopelman, Yael, Goldin, Eran, Dancour, Alan, Hants, Yael, Arbel-Alon, Sagit, Abramovitch, Rinat, Shemi, Amotz, Galun, Eithan
Published in Proceedings of the National Academy of Sciences - PNAS (17.12.2013)
Published in Proceedings of the National Academy of Sciences - PNAS (17.12.2013)
Get full text
Journal Article
Novel Kras-directed therapy in combination with chemotherapy for locally advanced pancreatic adenocarcinoma
Golan, Talia, Hubert, Ayala, Shemi, Amotz, Segal, Amiel, Khvalevsky, Elina Zorde, Domb, Avi, Ben-David, Eliel, Raskin, Stephen, Goldes, Yuri, Lahav, Maor, Dancour, Alan, Galun, Eithan
Published in Journal of clinical oncology (20.01.2014)
Published in Journal of clinical oncology (20.01.2014)
Get full text
Journal Article
A phase I trial of a local delivery of siRNA against k-ras in combination with chemotherapy for locally advanced pancreatic adenocarcinoma
Golan, Talia, Hubert, Ayala, Shemi, Amotz, Segal, Amiel, Dancour, Alan, Khvalevsky, Elina Zorde, Ben-David, Eliel, Raskin, Stephen, Goldes, Yuri, Inbar, Yael, Lahav, Maor, Domb, Avi, Galun, Eithan
Published in Journal of clinical oncology (20.05.2013)
Published in Journal of clinical oncology (20.05.2013)
Get full text
Journal Article